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Desmosterol is found in various organs of rats that show signs of myotonia in their skeletal muscle as a result of treatment with 20.25-
diazacholesterol. The amount of desmosterol depends on the time of treatment, and is different in different organs and different
kinds of muscle. The increase in desmosterol is much lower and the rats do not show any signs of myotonia when fed a cholesterol
rich diet in addition to treatment with 20.25-diazacholesterol. Treatment with triparanol also causes desmosterol accumulation but
in these rats myotonia is rarely observed.
Our results suggest that in the experimental animals myotonia becomes manifest when every second cholesterol molecule of the
muscle cell membrane is replaced by desmosterol. This is easily achieved in animals fed with 20.25-diazacholesterol but rarely occurs
with triparanol.
In verschiedenen Organen von Ratten, die mit 20.25-Diazacholesterin behandelt wurden und eine myotone Reaktion der Skelettmus-
kulatur zeigen, kann Desmosterin nachgewiesen werden. Der Desmosteringehalt hängt von der Behandlungsdauer ab und variiert von
Organ zu Organ. Auch die verschiedenen Muskeltypen zeigen Unterschiede.
Verfutterung einer cholesterinreichen Diät zusätzlich zur Behandlung mit 20.25-Diazacholesterin führt zu einem geringeren Des-
mosterinanstieg. Gleichzeitig wird auch die myotone Reaktion der Skelettmuskulatur verhindert.
In den Organen von Ratten, die mit Triparanol behandelt wurden, läßt sich ebenfalls Desmosterin nachweisen, eine Myotonie kann
aber nur in seltenen Fällen gefunden werden.
Unsere Ergebnisse lassen den Schluß zu, daß bei den behandelten Tieren myotone Reaktionen beobachtet werden können, wenn jedes
zweite Cholesterinmolekül der Muskelzellmembran durch Desmosterin ersetzt ist. Dies kann sehr leicht durch Gabe von 20.25-Diaza-
cholesterin erreicht werden, während eine Behandlung mit Triparanol nur in seltenen Fällen zu einem so hohen Desmosterinanteil
führt.
20.25-Diazacholesterol (Fig. l a) was synthesized for
the first time by Counsell et al. (1). These authors
reported the influence of the substance on cholesterol
biosynthesis. 20.25-Diazacholesterol inhibits the last
step of cholesterol biosynthesis, the reduction of des-
mosterol to cholesterol, resulting in accumulation of
desmosterol in liver (1) and serum (2) of rats treated
with this substance. Also an alteration of the fatty acid
pattern of membranal phospholipids was shown (3).
In 1959 triparanol (Fig. 1 b) was also shown to inhibit
the interconversion of desmosterol and cholesterol (4).
Bricker et al. (5) reported desmosterol accumulation in
serum and liver. They also reported the disappearance
of desmosterol in the treated rats by feeding a high
cholesterol diet.
While 20.25-diazacholesterol was shown to be able to
induce myotonia (6) and to aggravate already existing
myotonia (7), such an effect was not described for
triparanol (B).
In this study we present kinetic data on the replacement
of cholesterol by desmosterol in several organs of rats
treated with 20.25-diazacholesterol and triparanol. We
further present evidence for the role of desmosterol
incorporation in the development of the myotonic
reaction of skeletal muscle.
Fig. 1. Structural formulae of 20.25-diazacholesterol (a) and
triparanol (b).
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Methods
In each of 2 series of experiments 40 male Wistar rats with an
initial body weight of 160-170 g were divided into four groups.
The control group was treated daily with 0.2 ml water by an
esophageal tube; the rats referred to as 20.25-diazacholesterol
rats received 10 mg 20.25-diazacholesterol dihydrochloride
dissolved in 0.2 ml water per day, and the triparanol rats
received a suspension of 20 mg triparanol in 0.2 ml water per
day. These three groups were maintained on a standard rat
diet.
The fourth group was also given 10 mg 20.25-diazacholsterol
dihydrochloride in 0.2 ml water per day but was fed with a
cholesterol rich diet (2 g cholesterol/100 g standard diet).
After treatment for the number of days indicated in the figs,
a series of four rats consisting of one rat from each group was
anesthesized by ether, subjected to electromyography (for
details of the method see I.e. (7)) and then bled by puncture
of the abdominal aorta. The organs were quickly excised,
minced with scissors and homogenized in an Ultra-Turrax Mixer
at 0 °C. The erythrocytes separated from the plasma were
washed three times with ice-cold 9 g/1 NaCl.
After freeze-drying of the homogenates and erythrocyte sus-
pensions respectively the lipids were obtained quantitatively
by a threefold extraction with 20 vol. chloroform/methanol
(volumes, 20 ml + 10 ml) for one hour at room temperature.
According to Sperry (9) the lipids were purified, in one aliquot
of the extract the total sterol content was determined accor-·
ding to the Zak method (10) as modified by Winer et al. (2),
in another aliquot the sterols were separated from the other
lipids by thin-layer chromatography on silica gel with chloro-
form as solvent and were then eluted from the scraped off
silica gel with chloroform/methanol (volumes, 20 ml + 10 ml).
The percentage of cholesterol and desmosterol was determined
by a gas-liquid Chromatographie procedure in a Varian-aerograph
1400 using a 2 ft. column with 3% OV-17 on 120 mesh
Chromosorb Q: 250° C isotherm, N2 = 36 ml/min.; FID. This
procedure permits a clean separation of cholesterol and des-
mosterol (fig. 9), both substances giving the same molar re-
sponse as could be proved by the use of commercially avai-
lable standards (Merck, Darmstadt resp. Sigma, St. Louis). The
peaks were quantified by triangulation. 20.25-Diazacholesterol
was a gift from G. D. Searle, Chicago, USA. Triparanol was a
gift from Mereil Pharma, Gro Gerau.
Results
The total sterol content of various tissues of the control
rats can be seen from the table 1. As there were no
significant differences in the total sterol content in the
different groups of rats the values for the other three
groups are not shown in detail.
The increase of desmosterol in the sterol fraction of the
liver of the various groups of rats is shown in figure 2. The
desmosterol content of erythrocytes and lung increases
similarly. Therefore the latter results are not shown in
detail. There was no desmosterol in the control rats.
In the first weeks a linear increase of desmosterol is
observed reaching a plateau after about 20 days of treat-
ment. At that time the sterol fraction consists of about
88% desmosterol and even after treatment for 250 days
no further increase could be found in these organs.
In rats treated with triparanol such values were never
reached, but a plateau in the curve can also be seen
after treatment for about 20 dayst
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Fig. 2. Desmosterol increase in liver dependent on time of treat-
ment
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Since a cholesterol rich diet inhibits endogenous chole-
sterol biosynthesis, desmosterol accumulation is re-
duced. This clearly can be seen from the results obtained
with rats which received 20.25-diazacholesterol and
a 2% cholesterol diet. Although the total sterol content
remained unchanged in this group of rats, 38% desmoste-
rol in the sterol fraction of the above mentioned organs
was the maximal value observed.
For the kidney the results are shown in figure 3. Again
triparanol treatment was not as effective in exchanging
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Fig. 3. Desmosterol increase in kidney dependent on time of
treatment. Symbols see fig. 2.
Tab. 1. Total sterol content (mg/g wet weight ± S.D.) in
different tissues and in erythrocytes (mg/ml red blood
cells) of control rats, (n = 18)
Liver
Lung
Kidney
M. rectus femoris
Heart
M. soleus
N. ischiadicus
Brain
Erythrocytes
2.85 ± 0.21
4.35 ± 0.26
4.02 ±0.23
0.89 ± 0.05
1.55 ± 0.05
1.70 ±0.07
23.70 ± 0.38
18.23 ±0.31
0.93 ±0.10
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cholesterol for desmosterol but the preventive effect
of a cholesterol rich diet is found also for this organ.
Desmosterol accumulation in the different kinds of
muscles can be seen in figures 4—6. In all groups of rats
the highest desmosterol percentages are found in M.
rectus femoris, which is a fast-twitch white muscle (11),
and in the heart, whereas in M. soleus (slow-twitch
intermediate muscle) the desmosterol content increases
somewhat more slowly, the maximum incorporation
being the same at the end of the experiment.
Myotonia +
Myotonie (?)
10 15 20 25
Days of treatment
W 25θΓ
Fig. 4. Desmosterol increase in M. rectus femoris dependent on
time of treatment. Symbols see fig. 2.
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Fig. 5. Desmosterol increase in heart muscle dependent on time
of treatment. Symbols see fig. 2.
As in the other organs of the triparanol treated rates,
the desmosterol content of the muscles is less than in
the 20.25-diazacholesterol treated rats, and the preven-
tive effect of a cholesterol rich diet can also be seen
in all the muscles. Typical myotonic discharges in the
electromyogram could be demonstrated in the M. rectus
femoris of those animals that had a desmosterol percen-
tage higher than 60%, regardless of whether this percen-
tage was due to feeding 20.25-diazacholesterol or tri-
paranol; while for the animals with muscle desmosterol
in the range of about 40 to 60% (shaded in fig. 4) a
short lasting spontaneous activity was found in the
electromyogram.
A much different behaviour with regard to cholesterol
replacement by desmosterol can be seen in the brain
(fig. 8) and in the peripheral nerve (fig. 7). The increase
in desmosterol is very slow and, therefore, differences
between the three groups are not easily seen. Both
nervous tissues, i.e. brain and peripheral nerve, behaved
almost identically. Even after a 250 days treatment the
desmosterol content in brain and peripheral nerve is only
about 41 % of total sterols for 20.25-diazacholesterol
treated rats, 29% for the triparanol rats, and, as in other
organs, feeding a cholesterol rich diet additionally
diminishes the amount of incorporated desmosterol
(24%) after this time.
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Fig. 7. Desmosterol increase in N. ischiadicus dependent on
time of treatment. Symbols see fig. 2. The results for
the second series of rats were identical and are not
shown here.
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Fig. 6. Desmosterol increase in M. soleus dependent on time of
treatment. Symbols see fig. 2.
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Fig. 8. Desmosterol increase in the brain dependent on time of
treatment, Symbols see fig. 2. The results for the second
series of rats were identical and are not shown here.
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Fig. 9. Gas-chromatographic separation of cholesterol and des-
mosterol in peripheral nerve (m. ischiadicus).
,
 N desmosterol((a), - — - — = 0.404) and
total· s'terols
skelatal muscle (m. rectus femoris)
total sterols
of rats treated with 20.25-diazacholesterol for 250 days.
Figure 9 clearly demonstrates the differences in sterol
composition between skeletal muscle and nervous tissue
of a rat treated for 250 days with 20.25-diazacholeste-
rol.
Discussion
From the results of our experiments it can be clearly
seen that various organs behave differently with regard
to desmosterol accumulation after inhibition of des-
mosterol reductase by 20.25-diazacholesterol and tripara-
nol. The reason for this is not known. One could imagine
that replacement of cholesterol depends on the amount
of cholesterol originally present in the tissues. This could
explain the tremendously slow exchange that was found
in brain and peripheral nerve, for the content of
cholesterol in nervous tissues is about 6—7 times higher
than in the other investigated tissues, such as liver and
kidney (Tab. 1).
This could also explain the differences between fast-
twitch-white (i.e. M.rectus femoris) and slow-twitch-
intermediate (i.e. M. soleus) muscle, for it was shown
that the cholesterol content in various species is higher
in the slow-twitch-intermediate fiber than in the fast-
twitch white fiber (I.e. (12), and Tab. 1). Our findings
also reflect the rate of cholesterol turnover known to
be rather rapid in the liver, slower in tissues like muscles
and almost non-existent in nervous tissue, but we do
not know anything about the different affinities of
different tissues for cholesterol and desmosterol, re-
spectively. The finding that die desmosterol increase
in triparanol treated rats is4ower than in 20.25-diaza-
cholesterol treated rats may be due to,the fact that
triparanol is much less water soluble and can only be
given as a suspension and that triparanol is more toxic
than 20.25-diazacholesterol. We therefore did not
succeed in feeding rats with more than 2 mg triparanol
daily.
As early as 1966 Winer (8) suspected a participation of
desmosterol in the appearance of myotonic symptoms
in skeletal muscle, but he thought that additional factors
would have to be present, because in his experiments
triparanol failed to provoke myotonia.
Our results (fig. 4) are able to explain this discrepancy.
Clear cut myotonic discharges in the electromyogram
are obtained only when desmosterol makes up more
than 60% of total muscle sterols. It was shown that
there is a decrease in the desmosterol percentage from
total muscle to muscle cell membrane (13). This would
mean that myotonia becomes evident when about every
second cholesterol molecule is replaced by desmosterol
in the muscle cell membrane. This is easily achieved
with 20.25-diazacholesterol. But a replacement to such
an extent in our experiments happened only rarely
with triparanol.
Whenever the desmosterol percentage was in the range
between 40 to 60 percent (indicated in fig. 4 by shading)
typical myotonic runs were not found but some short
lasting spontaneous activity could clearly be seen.
The observation that the kinetics of cholesterol replace-
ment by desmosterol is slower in slow-twitch muscles
(fig. 6) than in fast-twitch muscles (fig. 4) fits well with
the finding that after treatment with azacholesterol·
myotonia appears later in slow-twitch than in fast-
twitch muscles (14).
From results concerning transport ATPases (15, 16, 17)
we have some evidence that the observed myotonia
after treatment with 20.25-diazacholesterol is due to
an alteration in the muscle cell membrane itself and is
not secondary or neurpgenic. The results reported in
this paper support this assumption for at the time
myotonia becomes evident in muscle only small changes
in the sterol fraction of the peripheral nerve (fig. 7) and
the brain (fig. 8) can be observed. There are no differ-
ences with regard to the desmosterol percentage in
nervous tissue between 20.25-dia2:acholesterol treated
rats being myotonic and those fed additionally a
cholesterol rich diet not showing any signs of myotonia.
In addition these findings show that 20.25-diazachol-
esterol itself is not the cause of the observed myotonia.
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